FDA Moves Forward on Aducanumab
By
Phil Gutis
| August 7th, 2020
In yet another encouraging step toward the development of what could be the first drug approved for Alzheimer’s disease, the Federal Drug Administration today…
Phil’s Journal: Being Part of Scientific History, or, a New Phase of the Biogen Trial
By
Phil Gutis
| July 16th, 2020
The latest news about Biogen’s controversial Alzheimer’s drug popped into my email at 8:26 a.m. last Wednesday. Coincidentally it arrived just as I was…
Biogen Seeks FDA Approval for Alzheimer’s Drug Aducanumab
By
Phil Gutis
| July 8th, 2020
In another step toward what could be the first treatment for early stage Alzheimer’s, Biogen and Eisai today said they have completed an application…
Phil’s Journal: Waiting While Approval for Biogen’s Alzheimer’s Drug is Delayed, Yet Again
By Phil Gutis | April 23rd, 2020
Hours feel like days. Days feel like months. And months? Well they can feel like a decade. Particularly when you are awaiting the restart…
Phil’s Journal: My Good Friend Is the First to Receive Biogen’s Alzheimer’s Drug in New Trial
By Phil Gutis | March 13th, 2020
Being Patient Senior Reporter Phil Gutis spent the day with our patient advisor, Jeff Borghoff, who was the first recipient in Biogen’s latest trial…
Biogen Spends $350 Million to Develop Gene Therapies For Alzheimer’s, Parkinson’s
By Phil Gutis | March 3rd, 2020
Frustrated for decades with failure after failure in efforts to find effective medications to treat Alzheimer’s and other cognitive disorders, researchers are now increasingly…
Phil’s Journal: When Alzheimer’s Trials Are Cancelled, Notifying Study Participants in the Most ‘Humane’ Way
By Phil Gutis | February 28th, 2020
Almost a year ago, the phones and social media feeds of about 4,000 people around the world began to explode. Biogen had unexpectedly—and quite…
Follow us